Combined factor IIa and Xa inhibitor therapy for thrombosis whilst on therapeutic anticoagulant. Issue 143 (July 2016)

• Record Type: Journal Article
• Authors: Arachchillage, Deepa R.J.; Besser, Martin; Maclean, Rhona; Baglin, Trevor; van Veen, Joost J.
• Is Part Of: Thrombosis research. Issue 143(2016)
• Page Start: 137
• Page End: 140
• Publication Date: 2016-07
• Subjects: Recurrent venous thrombosis -- Dabigatran -- Apixaban -- Rivaroxaban -- Argatroban -- Cancer; Thrombosis -- Periodicals; 616.135
• DOI: 10.1016/j.thromres.2016.05.007
• Languages: English
• ISSNs: 0049-3848

Abstract

Highlights: Low molecular weight heparin (LMWH) is the treatment of choice in cancer related VTE. Managing cancer related recurrent VTE on therapeutic anticoagulation is a challenge. Current guidelines recommend dose escalation of LMWH with ant-Xa monitoring. Combined factor Xa $_amp_$amp; factor IIa inhibitors may be an option in refractory thrombosis.